199 related articles for article (PubMed ID: 12689746)
61. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy.
Costa-Dookhan KA; Agarwal SM; Chintoh A; Tran VN; Stogios N; Ebdrup BH; Sockalingam S; Rajji TK; Remington GJ; Siskind D; Hahn MK
Expert Opin Drug Saf; 2020 Jan; 19(1):43-57. PubMed ID: 31770500
[No Abstract] [Full Text] [Related]
62. Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics.
Raper J; Morrison RD; Daniels JS; Howell L; Bachevalier J; Wichmann T; Galvan A
ACS Chem Neurosci; 2017 Jul; 8(7):1570-1576. PubMed ID: 28324647
[TBL] [Abstract][Full Text] [Related]
63. Variability of the in vivo metabolism of clozapine.
Raedler TJ; Hinkelmann K; Wiedemann K
Clin Neuropharmacol; 2008; 31(6):347-52. PubMed ID: 19050412
[TBL] [Abstract][Full Text] [Related]
64. Weight gain during a double-blind multidosage clozapine study.
de Leon J; Diaz FJ; Josiassen RC; Cooper TB; Simpson GM
J Clin Psychopharmacol; 2007 Feb; 27(1):22-7. PubMed ID: 17224708
[TBL] [Abstract][Full Text] [Related]
65. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration.
Yusufi B; Mukherjee S; Flanagan R; Paton C; Dunn G; Page E; Barnes TR
Int Clin Psychopharmacol; 2007 Jul; 22(4):238-43. PubMed ID: 17519648
[TBL] [Abstract][Full Text] [Related]
66. Another use of silica gel and aqueous eluent for HPLC analysis of clozapine and desmethylclozapine.
Coudoré F; Nicolay A; Hoareau M; Eschalier A
J Anal Toxicol; 1999; 23(3):195-9. PubMed ID: 10369329
[TBL] [Abstract][Full Text] [Related]
67. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study.
Ng W; Uchida H; Ismail Z; Mamo DC; Rajji TK; Remington G; Sproule B; Pollock BG; Mulsant BH; Bies RR
Ther Drug Monit; 2009 Jun; 31(3):360-6. PubMed ID: 19349931
[TBL] [Abstract][Full Text] [Related]
68. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
[TBL] [Abstract][Full Text] [Related]
69. Clozapine and Norclozapine Plasma Levels in Patients Switched Between Different Liquid Formulations.
Oloyede E; Dzahini O; Whiskey E; Taylor D
Ther Drug Monit; 2020 Jun; 42(3):491-496. PubMed ID: 31652191
[TBL] [Abstract][Full Text] [Related]
70. Effect of Coffee and Chocolate Ingestion on Clozapine Dose and on Plasma Clozapine and Norclozapine Concentrations in Clinical Practice.
Flanagan RJ; Obee SJ; Kim AHM; Every-Palmer S
J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):161-167. PubMed ID: 38421925
[TBL] [Abstract][Full Text] [Related]
71. Comedication of Valproic Acid Is Associated With Increased Metabolism of Clozapine.
Hommers L; Scharl M; Hefner G; Hohner M; Fischer M; Pfuhlmann B; Deckert J; Unterecker S
J Clin Psychopharmacol; 2018 Jun; 38(3):188-192. PubMed ID: 29620699
[TBL] [Abstract][Full Text] [Related]
72. Pharmacokinetic changes of clozapine and norclozapine in a rat model of non-alcoholic fatty liver disease induced by orotic acid.
Li Z; Lee SH; Jeong HJ; Kang HE
Xenobiotica; 2021 Mar; 51(3):324-334. PubMed ID: 33185134
[TBL] [Abstract][Full Text] [Related]
73. Clozapine: more than 900 mg/day may be needed.
Maccall C; Billcliff N; Igbrude W; Natynczuk S; Spencer EP; Flanagan RJ
J Psychopharmacol; 2009 Mar; 23(2):206-10. PubMed ID: 18515467
[TBL] [Abstract][Full Text] [Related]
74. Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia.
Frazier JA; Cohen LG; Jacobsen L; Grothe D; Flood J; Baldessarini RJ; Piscitelli S; Kim GS; Rapoport JL
J Clin Psychopharmacol; 2003 Feb; 23(1):87-91. PubMed ID: 12544379
[TBL] [Abstract][Full Text] [Related]
75. Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients.
Mauri M; Volonteri LS; Fiorentini A; Invernizzi G; Nerini T; Baldi M; Bareggi SR
Schizophr Res; 2004 Feb; 66(2-3):197-8. PubMed ID: 15061256
[No Abstract] [Full Text] [Related]
76. Ultra-fast LC-MS/MS in therapeutic drug monitoring: Quantification of clozapine and norclozapine in human plasma.
Couchman L; Fisher DS; Subramaniam K; Handley SA; Boughtflower RJ; Benton CM; Flanagan RJ
Drug Test Anal; 2018 Feb; 10(2):323-329. PubMed ID: 28585411
[TBL] [Abstract][Full Text] [Related]
77. Tissue concentrations of clozapine and its metabolites in the rat.
Baldessarini RJ; Centorrino F; Flood JG; Volpicelli SA; Huston-Lyons D; Cohen BM
Neuropsychopharmacology; 1993 Sep; 9(2):117-24. PubMed ID: 8216694
[TBL] [Abstract][Full Text] [Related]
78. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables.
Diaz FJ; Santoro V; Spina E; Cogollo M; Rivera TE; Botts S; de Leon J
Pharmacopsychiatry; 2008 May; 41(3):81-91. PubMed ID: 18484549
[TBL] [Abstract][Full Text] [Related]
79. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia.
Xiang YQ; Zhang ZJ; Weng YZ; Zhai YM; Li WB; Cai ZJ; Tan QR; Wang CY
Schizophr Res; 2006 Apr; 83(2-3):201-10. PubMed ID: 16524698
[TBL] [Abstract][Full Text] [Related]
80. Effect of influenza vaccination on serum clozapine and its main metabolite concentrations in patients with schizophrenia.
Raaska K; Raitasuo V; Neuvonen PJ
Eur J Clin Pharmacol; 2001 Dec; 57(10):705-8. PubMed ID: 11829199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
